<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02930889</url>
  </required_header>
  <id_info>
    <org_study_id>RAD-2016-24154</org_study_id>
    <nct_id>NCT02930889</nct_id>
  </id_info>
  <brief_title>Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)</brief_title>
  <official_title>Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a investigator-initiated evaluation of the safety and efficacy of treating benign&#xD;
      prostatic hyperplasia (BPH) by prostatic artery embolization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a investigator-initiated evaluation of the safety and efficacy of treating benign&#xD;
      prostatic hyperplasia (BPH) by prostatic artery embolization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">October 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 Months</time_frame>
    <description>All adverse events will be collected and reviewed. Outcome is reported as the total number of adverse events reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in International Prostate Symptom Score</measure>
    <time_frame>3 months</time_frame>
    <description>The International Prostate Symptom Score assesses the severity of symptoms in benign prostatic hypertrophy. The questionnaire contains seven items rated on a scale from one to five. Total scores are a sum of items scores with higher scores indicating worse BPH symptoms. Outcome is reported as the change in IPS score from baseline to three months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Quality of Life Scale (QOLS)</measure>
    <time_frame>3 months</time_frame>
    <description>Participants will complete the Quality of Life Scale (QOLS), which contains 15 items measuring five domains of quality of life. Total scores are a sum of item scores and range from 16 to 112, with higher scores indicating a better quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Change in Medication Use</measure>
    <time_frame>3 months</time_frame>
    <description>Participants will report change in medication use for prostate symptoms. The number of participants who reduce medications will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Measured by MTOPS or Flow Rate Change</measure>
    <time_frame>3 months</time_frame>
    <description>Outcome is reported as the number of participants who experience treatment efficacy as defined by a Medical Therapy of Prostatic Symptoms (MTOPS) composite variable symptom score greater than 30 and/or flow rate change of 15 millimeters per second or greater.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Prostate Artery Embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prostate Artery Embolization</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prostate Artery Embolization</intervention_name>
    <description>Prostate Artery Embolization</description>
    <arm_group_label>Prostate Artery Embolization</arm_group_label>
    <other_name>PAE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, 45 years or older&#xD;
&#xD;
          -  Diagnosis of Lower Urinary Tract Symptoms from Benign Prostatic Hyperplasia refractory&#xD;
             to medical therapy for at least 6 months.&#xD;
&#xD;
          -  IPSS score at initial evaluation should be greater than 12, and uroflowmetry (Qmax) of&#xD;
             &lt;15mL/s (milliliters per second).&#xD;
&#xD;
          -  All prostate volumes will be &gt; 40gm&#xD;
&#xD;
          -  PSA which meets one of the following criteria:Baseline PSA ≤ 2.5ng/mL, Baseline PSA &gt;&#xD;
             2.5 ng/mL and ≤ 10 ng/mL AND free PSA ≥ 25% of total PSA (no biopsy required);Baseline&#xD;
             PSA &gt; 2.5 ng/mL and ≤ 10 ng/mL AND free PSA &lt; 25% of total PSA AND negative prostate&#xD;
             biopsy result (minimum of 12 core biopsy) within 12 months;Baseline PSA &gt;10 ng/mL AND&#xD;
             negative prostate biopsy result (minimum of 12 core biopsy) within 12 months;Negative&#xD;
             prostate biopsy (minimum 12 cores within 12 months) if abnormal digital rectal&#xD;
             examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active urinary tract infections or recurrent urinary tract infections (&gt;&#xD;
             2/year), prostatitis, or interstitial cystitis.&#xD;
&#xD;
          -  Cases of biopsy proven prostate, bladder, or urethral cancer.&#xD;
&#xD;
          -  Patients on long-term narcotic analgesia, androgen therapy, or GNRH&#xD;
             (gonadotropin-releasing hormone) analogue therapy who are unwilling to stop therapy&#xD;
             for 2 months prior to the study.&#xD;
&#xD;
          -  Use of anithistamines, anti-convulsants, and antispasmodics within one week of&#xD;
             treatment unless they have been treated with the same drug (at the same dosage) for at&#xD;
             least 6 months and has an associated stable voiding pattern.&#xD;
&#xD;
          -  Patients who are classified as New York Heart Association Class III (Moderate), or&#xD;
             higher, have cardiac arrhythmias, have uncontrolled diabetes, or are known to be&#xD;
             immunosuppressed.&#xD;
&#xD;
          -  Hypersensitivity reactions to contrast material not manageable with prophylaxis.&#xD;
&#xD;
          -  Patients with glomerular filtration rates less than 40 who are not already on dialysis&#xD;
&#xD;
          -  Prostate volume &lt;40 mL&#xD;
&#xD;
          -  Patients with bilateral internal iliac arterial occlusion&#xD;
&#xD;
          -  Patients with causes of bladder obstruction not due to BPH (eg urethral stricture,&#xD;
             bladder neck contraction, etc)&#xD;
&#xD;
          -  Patients with neurogenic or bladder atonia&#xD;
&#xD;
          -  Prior prostatectomy&#xD;
&#xD;
          -  Cystolithiasis within the last 3 months&#xD;
&#xD;
          -  Patients interested in future fertility&#xD;
&#xD;
          -  Patients with a life expectancy less than 1 year&#xD;
&#xD;
          -  Patients where embolization is not possible distal to collateral vessels feeding&#xD;
             non-prostatic tissue&#xD;
&#xD;
          -  Patients with major neurologic illnesses which could have symptoms that may be similar&#xD;
             to or confused for BPH (eg Parkinson's disease, multiple sclerosis, Shy-Drager&#xD;
             syndrome, spinal cord injury, etc.).&#xD;
&#xD;
          -  Patients with urethral stents&#xD;
&#xD;
          -  Patients who have undergone prior rectal surgery other than hemorrhoidectomy or pelvic&#xD;
             irradiation.&#xD;
&#xD;
          -  Patients who have started or changed their dosage of alpha blockers or 5-alpha&#xD;
             reductase inhibitors in the month prior to PAE&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jafar Golzarian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 10, 2016</study_first_submitted>
  <study_first_submitted_qc>October 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2016</study_first_posted>
  <results_first_submitted>October 14, 2021</results_first_submitted>
  <results_first_submitted_qc>October 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 15, 2021</results_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic Embolization</keyword>
  <keyword>Prostatic Artery Embolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02930889/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02930889/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prostate Artery Embolization</title>
          <description>Prostate Artery Embolization&#xD;
Prostate Artery Embolization: Prostate Artery Embolization</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet inclusion/exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants from whom data was collected are included.</population>
      <group_list>
        <group group_id="B1">
          <title>Prostate Artery Embolization</title>
          <description>Prostate Artery Embolization&#xD;
Prostate Artery Embolization: Prostate Artery Embolization</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.2" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>All adverse events will be collected and reviewed. Outcome is reported as the total number of adverse events reported.</description>
        <time_frame>3 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization</title>
            <description>Prostate Artery Embolization&#xD;
Prostate Artery Embolization: Prostate Artery Embolization</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>All adverse events will be collected and reviewed. Outcome is reported as the total number of adverse events reported.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in International Prostate Symptom Score</title>
        <description>The International Prostate Symptom Score assesses the severity of symptoms in benign prostatic hypertrophy. The questionnaire contains seven items rated on a scale from one to five. Total scores are a sum of items scores with higher scores indicating worse BPH symptoms. Outcome is reported as the change in IPS score from baseline to three months.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization</title>
            <description>Prostate Artery Embolization&#xD;
Prostate Artery Embolization: Prostate Artery Embolization</description>
          </group>
        </group_list>
        <measure>
          <title>Change in International Prostate Symptom Score</title>
          <description>The International Prostate Symptom Score assesses the severity of symptoms in benign prostatic hypertrophy. The questionnaire contains seven items rated on a scale from one to five. Total scores are a sum of items scores with higher scores indicating worse BPH symptoms. Outcome is reported as the change in IPS score from baseline to three months.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.40" spread="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Quality of Life Scale (QOLS)</title>
        <description>Participants will complete the Quality of Life Scale (QOLS), which contains 15 items measuring five domains of quality of life. Total scores are a sum of item scores and range from 16 to 112, with higher scores indicating a better quality of life.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization</title>
            <description>Prostate Artery Embolization&#xD;
Prostate Artery Embolization: Prostate Artery Embolization</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life Scale (QOLS)</title>
          <description>Participants will complete the Quality of Life Scale (QOLS), which contains 15 items measuring five domains of quality of life. Total scores are a sum of item scores and range from 16 to 112, with higher scores indicating a better quality of life.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.80" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Reported Change in Medication Use</title>
        <description>Participants will report change in medication use for prostate symptoms. The number of participants who reduce medications will be reported.</description>
        <time_frame>3 months</time_frame>
        <population>Measure was only collected from 2 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization</title>
            <description>Prostate Artery Embolization&#xD;
Prostate Artery Embolization: Prostate Artery Embolization</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Change in Medication Use</title>
          <description>Participants will report change in medication use for prostate symptoms. The number of participants who reduce medications will be reported.</description>
          <population>Measure was only collected from 2 participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Measured by MTOPS or Flow Rate Change</title>
        <description>Outcome is reported as the number of participants who experience treatment efficacy as defined by a Medical Therapy of Prostatic Symptoms (MTOPS) composite variable symptom score greater than 30 and/or flow rate change of 15 millimeters per second or greater.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization</title>
            <description>Prostate Artery Embolization&#xD;
Prostate Artery Embolization: Prostate Artery Embolization</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Measured by MTOPS or Flow Rate Change</title>
          <description>Outcome is reported as the number of participants who experience treatment efficacy as defined by a Medical Therapy of Prostatic Symptoms (MTOPS) composite variable symptom score greater than 30 and/or flow rate change of 15 millimeters per second or greater.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prostate Artery Embolization</title>
          <description>Prostate Artery Embolization&#xD;
Prostate Artery Embolization: Prostate Artery Embolization</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Loose Stool</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Burning Sensation While Urinating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood in Urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Post Procedure Penile Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jafar Golzarian, MD</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-626-5566</phone>
      <email>jafar@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

